GeneReach Biotechnology (Taiwan) Buy Hold or Sell Recommendation
| 4171 Stock | TWD 27.25 1.10 3.88% |
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding GeneReach Biotechnology is 'Cautious Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell GeneReach Biotechnology given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for GeneReach Biotechnology, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out GeneReach Biotechnology Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as GeneReach and provide practical buy, sell, or hold advice based on investors' constraints. GeneReach Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
GeneReach |
Execute GeneReach Biotechnology Buy or Sell Advice
The GeneReach recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on GeneReach Biotechnology. Macroaxis does not own or have any residual interests in GeneReach Biotechnology or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute GeneReach Biotechnology's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
GeneReach Biotechnology Trading Alerts and Improvement Suggestions
| GeneReach Biotechnology generated a negative expected return over the last 90 days | |
| About 35.0% of the company shares are owned by insiders or employees |
GeneReach Biotechnology Returns Distribution Density
The distribution of GeneReach Biotechnology's historical returns is an attempt to chart the uncertainty of GeneReach Biotechnology's future price movements. The chart of the probability distribution of GeneReach Biotechnology daily returns describes the distribution of returns around its average expected value. We use GeneReach Biotechnology price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of GeneReach Biotechnology returns is essential to provide solid investment advice for GeneReach Biotechnology.
| Mean Return | -0.21 | Value At Risk | -1.72 | Potential Upside | 1.21 | Standard Deviation | 1.14 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of GeneReach Biotechnology historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
GeneReach Biotechnology Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to GeneReach Biotechnology or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that GeneReach Biotechnology's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a GeneReach stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.22 | |
β | Beta against Dow Jones | -0.01 | |
σ | Overall volatility | 1.16 | |
Ir | Information ratio | -0.28 |
GeneReach Biotechnology Volatility Alert
GeneReach Biotechnology exhibits very low volatility with skewness of -1.25 and kurtosis of 3.36. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure GeneReach Biotechnology's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact GeneReach Biotechnology's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.GeneReach Biotechnology Fundamentals Vs Peers
Comparing GeneReach Biotechnology's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze GeneReach Biotechnology's direct or indirect competition across all of the common fundamentals between GeneReach Biotechnology and the related equities. This way, we can detect undervalued stocks with similar characteristics as GeneReach Biotechnology or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of GeneReach Biotechnology's fundamental indicators could also be used in its relative valuation, which is a method of valuing GeneReach Biotechnology by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare GeneReach Biotechnology to competition |
| Fundamentals | GeneReach Biotechnology | Peer Average |
| Return On Equity | 0.3 | -0.31 |
| Return On Asset | 0.13 | -0.14 |
| Profit Margin | 0.38 % | (1.27) % |
| Operating Margin | 0.43 % | (5.51) % |
| Current Valuation | 2.09 B | 16.62 B |
| Shares Outstanding | 45.97 M | 571.82 M |
| Shares Owned By Insiders | 34.96 % | 10.09 % |
| Shares Owned By Institutions | 4.57 % | 39.21 % |
| Price To Earning | 8.39 X | 28.72 X |
| Price To Book | 2.37 X | 9.51 X |
| Price To Sales | 2.88 X | 11.42 X |
| Revenue | 1.01 B | 9.43 B |
| Gross Profit | 746.98 M | 27.38 B |
| EBITDA | 535.64 M | 3.9 B |
| Net Income | 376.62 M | 570.98 M |
| Cash And Equivalents | 811.4 M | 2.7 B |
| Cash Per Share | 17.65 X | 5.01 X |
| Total Debt | 217.39 M | 5.32 B |
| Debt To Equity | 0.30 % | 48.70 % |
| Current Ratio | 5.21 X | 2.16 X |
| Book Value Per Share | 24.36 X | 1.93 K |
| Cash Flow From Operations | 348.99 M | 971.22 M |
| Earnings Per Share | 6.90 X | 3.12 X |
| Number Of Employees | 16 | 18.84 K |
| Beta | 0.63 | -0.15 |
| Market Capitalization | 2.73 B | 19.03 B |
| Total Asset | 1.68 B | 29.47 B |
| Z Score | 7.2 | 8.72 |
| Annual Yield | 0.08 % | |
| Net Asset | 1.68 B | |
| Last Dividend Paid | 4.55 |
GeneReach Biotechnology Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as GeneReach . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 4048.52 | |||
| Daily Balance Of Power | (0.79) | |||
| Rate Of Daily Change | 0.96 | |||
| Day Median Price | 27.95 | |||
| Day Typical Price | 27.72 | |||
| Price Action Indicator | (1.25) | |||
| Period Momentum Indicator | (1.10) |
About GeneReach Biotechnology Buy or Sell Advice
When is the right time to buy or sell GeneReach Biotechnology? Buying financial instruments such as GeneReach Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having GeneReach Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cryptocurrency Thematic Idea Now
Cryptocurrency
Dynamically computed list of top cryptocurrencies sorted bymarket capitalization. The Cryptocurrency theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cryptocurrency Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for GeneReach Stock Analysis
When running GeneReach Biotechnology's price analysis, check to measure GeneReach Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneReach Biotechnology is operating at the current time. Most of GeneReach Biotechnology's value examination focuses on studying past and present price action to predict the probability of GeneReach Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneReach Biotechnology's price. Additionally, you may evaluate how the addition of GeneReach Biotechnology to your portfolios can decrease your overall portfolio volatility.